Schizophrenic Disorders Clinical Trial
Auditory hallucinations are common (present in 60-70% of cases) and extremely debilitating.
Behavioral disorders associated with them can have serious social repercussions. However, in
25% of cases the usual antipsychotic drug treatments are incompletely or totally
ineffective.
Fifteen subjects will be included after collection and signed their informed consent.
The rTMS treatment is made of 4 sessions of 13 minutes spread over two days, at a frequency
of 20 Hz and an intensity of 80% of motor threshold at rest. These constants are used to
stay below the risk of occurrence of seizures, the only serious side effects identified.
Furthermore the rTMS treatment is almost painless: tension headaches are the main side
effects and make amends with simple analgesics. rTMS is devoid of neurocognitive effects.
The LEFT stimulation site will be established through a anatomofunctional imaging before
treatment (between D-7 and D0).
Treatment efficacy will be evaluated daily during treatment (days 1 and 2) and during the
first 2 weeks of starting treatment.
n/a
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04608032 -
Neuropsychological Assessment of Remediation for Cognitive Impairments in Schizophrenia
|
N/A | |
| Terminated |
NCT00660595 -
Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
|
Phase 3 | |
| Completed |
NCT02655172 -
Have a Good Grasp of the Worldthe World
|
N/A | |
| Completed |
NCT01606436 -
A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia
|
Phase 1 | |
| Completed |
NCT01729650 -
Effectiveness of a Physical Activity and Diet Program in Patients With Psychotic Disorder (CapiCor)
|
N/A | |
| Completed |
NCT00488319 -
Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.
|
Phase 3 | |
| Completed |
NCT00088491 -
Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia
|
Phase 3 | |
| Completed |
NCT01279213 -
Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia
|
Phase 4 | |
| Completed |
NCT00600756 -
Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone
|
Phase 3 | |
| Completed |
NCT00572247 -
The Psychiatric Rehabilitation Approach to Weight Loss
|
N/A | |
| Completed |
NCT00491569 -
Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia
|
Phase 2 | |
| Completed |
NCT00328276 -
Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia
|
Phase 2 | |
| Completed |
NCT00485823 -
Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia
|
Phase 4 | |
| Active, not recruiting |
NCT00161408 -
Psychological Intervention for Relapse Prevention in First Episode Schizophrenia
|
N/A | |
| Terminated |
NCT05164289 -
Interest of EMDR Schizophrenic Disorders
|
||
| Withdrawn |
NCT00276263 -
Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia
|
Phase 2 | |
| Completed |
NCT00088465 -
Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 3 | |
| Withdrawn |
NCT02654405 -
Sodium Butyrate For Improving Cognitive Function In Schizophrenia
|
Phase 2/Phase 3 | |
| Completed |
NCT02544516 -
Upside Down, Give me the Handle
|
N/A | |
| Completed |
NCT00960219 -
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia
|
Phase 2 |